Literature DB >> 25253228

How long should we continue prednisone after abiraterone discontinuation?

Karen Le, Anna Milanesi, Jane E Weinreb.   

Abstract

Entities:  

Year:  2014        PMID： 25253228      PMCID： PMC4755326     

Source DB:  PubMed          Journal:  Endocr Pract        ISSN： 1530-891X            Impact factor:   3.443


× No keyword cloud information.
  4 in total

1.  Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.

Authors:  Karim Fizazi; Howard I Scher; Arturo Molina; Christopher J Logothetis; Kim N Chi; Robert J Jones; John N Staffurth; Scott North; Nicholas J Vogelzang; Fred Saad; Paul Mainwaring; Stephen Harland; Oscar B Goodman; Cora N Sternberg; Jin Hui Li; Thian Kheoh; Christopher M Haqq; Johann S de Bono
Journal:  Lancet Oncol       Date:  2012-09-18       Impact factor: 41.316

2.  Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

Authors:  Charles J Ryan; Matthew R Smith; Lawrence Fong; Jonathan E Rosenberg; Philip Kantoff; Florence Raynaud; Vanessa Martins; Gloria Lee; Thian Kheoh; Jennifer Kim; Arturo Molina; Eric J Small
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

3.  Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.

Authors:  Gerhardt Attard; Alison H M Reid; Richard J Auchus; Beverly A Hughes; Amy Mulick Cassidy; Emilda Thompson; Nikhil Babu Oommen; Elizabeth Folkerd; Mitch Dowsett; Wiebke Arlt; Johann S de Bono
Journal:  J Clin Endocrinol Metab       Date:  2011-12-14       Impact factor: 5.958

Review 4.  Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer.

Authors:  Roberta Ferraldeschi; Nima Sharifi; Richard J Auchus; Gerhardt Attard
Journal:  Clin Cancer Res       Date:  2013-03-07       Impact factor: 12.531
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.